Martin A. Lehr
Net Worth

Last updated:

What is Martin A. Lehr net worth?

The estimated net worth of Mr. Martin A. Lehr is at least $1,140,090 as of 21 Feb 2023. He owns shares worth $140,090 as insider and has received compensation worth at least $1,000,000 in Context Therapeutics Inc..

What is the salary of Martin A. Lehr?

Mr. Martin A. Lehr salary is $250,000 per year as Co-Founder, Chief Executive Officer & Director in Context Therapeutics Inc..

How old is Martin A. Lehr?

Mr. Martin A. Lehr is 41 years old, born in 1984.

What stocks does Martin A. Lehr currently own?

As insider, Mr. Martin A. Lehr owns shares in one company:

Company Title Shares Price per share Total value
Context Therapeutics Inc. (CNTX) Co-Founder, Chief Executive Officer & Director 159,701 $0.88 $140,090

What does Context Therapeutics Inc. do?

Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

CNTX logo
CNTX
Context Therapeutics Inc.
$0.88

Martin A. Lehr insider trading

Context Therapeutics Inc.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 5,823 $0.84 $4,903
Purchase
Common Stock 5,606 $0.87 $4,900
Purchase
Common Stock 5,040 $0.97 $4,899
Purchase
Common Stock 7,027 $0.7 $4,898
Purchase
Common Stock 6,839 $0.72 $4,904
Purchase
Common Stock 6,783 $0.74 $4,992
Purchase
Common Stock 20,000 $0.74 $14,800
Purchase
Common Stock 13,000 $1.85 $24,063
Purchase
Common Stock 13,000 $3.22 $41,847
Purchase
Common Stock 10,000 $5 $50,000

Context Therapeutics key executives

Context Therapeutics Inc. executives and other stock owners filed with the SEC:

  • Dr. Tarek Sahmoud M.D., Ph.D. (64) Chief Medical Officer
  • Dr. William F. Rencher Ph.D. (66) Head of CMC & Regulatory
  • Mr. Martin A. Lehr (41) Co-Founder, Chief Executive Officer & Director